CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 986 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06615401
NCT06615401N/ACompleted

Understanding Perceived Access and Receipt of Gender-affirming Treatments Among Transgender Veterans

VA Office of Research and Development·observational·Posted Sep 26, 2024·Updated Jan 28, 2026

In Brief

An observational study for Gender Dysphoria. Completed, enrolled 986 participants across 1 site.

Detailed Summary

Transgender Veterans (trans Vets) frequently experience gender dysphoria or distress related to discord between their gender identity and birth sex. Gender-affirming treatments (GATs) are medically necessary treatments to reduce gender dysphoria. However, not much is known about the barriers and facilitators that influence GAT access and receipt in VA and VA Community Care (CC), among trans Vets who desire GATs. The goals of this mixed-methods study are to determine which GATs trans Vets receive and in which setting, identify barriers and facilitators associated with desired GAT receipt in VA and CC, examine association of GAT receipt, specifically mental healthcare and hormone therapy, with mental health and suicide risk and understand trans Vet experiences related to receipt and desire for mental healthcare and hormone therapy in VA and CC.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20252026
First PostedSep 26, 2024
Enrollment StartOct 1, 2024
Primary CompletionJan 18, 2025
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 1.8 years ago